Literature DB >> 32482754

The increasing complexity of the management of core-binding factor acute myeloid leukemia.

Mark R Litzow1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32482754      PMCID： PMC7271610          DOI： 10.3324/haematol.2020.249110

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Krzysztof Mrózek; Amy S Ruppert; Kati Maharry; Jonathan E Kolitz; Joseph O Moore; Robert J Mayer; Mark J Pettenati; Bayard L Powell; Colin G Edwards; Lisa J Sterling; James W Vardiman; Charles A Schiffer; Andrew J Carroll; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Precision oncology for acute myeloid leukemia using a knowledge bank approach.

Authors:  Moritz Gerstung; Elli Papaemmanuil; Inigo Martincorena; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Michael Heuser; Felicitas Thol; Niccolo Bolli; Peter Ganly; Arnold Ganser; Ultan McDermott; Konstanze Döhner; Richard F Schlenk; Hartmut Döhner; Peter J Campbell
Journal:  Nat Genet       Date:  2017-01-16       Impact factor: 38.330

Review 3.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

4.  Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Authors:  Nicolas Duployez; Alice Marceau-Renaut; Nicolas Boissel; Arnaud Petit; Maxime Bucci; Sandrine Geffroy; Hélène Lapillonne; Aline Renneville; Christine Ragu; Martin Figeac; Karine Celli-Lebras; Catherine Lacombe; Jean-Baptiste Micol; Omar Abdel-Wahab; Pascale Cornillet; Norbert Ifrah; Hervé Dombret; Guy Leverger; Eric Jourdan; Claude Preudhomme
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 5.  The myth of the second remission of acute leukemia in the adult.

Authors:  Stephen J Forman; Jacob M Rowe
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

Review 6.  Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.

Authors:  Hossein Ayatollahi; Arezoo Shajiei; Mohammad Hadi Sadeghian; Maryam Sheikhi; Ehsan Yazdandoust; Masumeh Ghazanfarpour; Seyyede Fatemeh Shams; Sepideh Shakeri
Journal:  Hematol Oncol Stem Cell Ther       Date:  2016-09-03

Review 7.  Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

Authors:  Robert K Hills; Sylvie Castaigne; Frederick R Appelbaum; Jacques Delaunay; Stephen Petersdorf; Megan Othus; Elihu H Estey; Hervé Dombret; Sylvie Chevret; Norbert Ifrah; Jean-Yves Cahn; Christian Récher; Lucy Chilton; Anthony V Moorman; Alan K Burnett
Journal:  Lancet Oncol       Date:  2014-07-06       Impact factor: 41.316

8.  Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.

Authors:  Marie-Anne Hospital; Thomas Prebet; Sarah Bertoli; Xavier Thomas; Emmanuelle Tavernier; Thorsten Braun; Cécile Pautas; Aurore Perrot; Bruno Lioure; Philippe Rousselot; Jérôme Tamburini; Thomas Cluzeau; Johanna Konopacki; Edouard Randriamalala; Céline Berthon; Marie-Pierre Gourin; Christian Recher; Jean-Yves Cahn; Norbert Ifrah; Hervé Dombret; Nicolas Boissel
Journal:  Blood       Date:  2014-07-08       Impact factor: 22.113

9.  Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Kazimierz Halaburda; Myriam Labopin; Audrey Mailhol; Gerard Socié; Charles Craddock; Mahmoud Aljurf; Dietrich Beelen; Jan J Cornelissen; Jean-Henri Bourhis; Hélène Labussière-Wallet; Didier Blaise; Tobias Gedde-Dahl; Maria Gilleece; Ibrahim Yakoub-Agha; Ghulam Mufti; Jordi Esteve; Mohamad Mohty; Arnon Nagler
Journal:  Haematologica       Date:  2019-08-22       Impact factor: 9.941

10.  Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

Authors:  Celalettin Ustun; Elizabeth Morgan; Erica E M Moodie; Sheeja Pullarkat; Cecilia Yeung; Sigurd Broesby-Olsen; Robert Ohgami; Young Kim; Wolfgang Sperr; Hanne Vestergaard; Dong Chen; Philip M Kluin; Michelle Dolan; Krzysztof Mrózek; David Czuchlewski; Hans-Peter Horny; Tracy I George; Thomas Kielsgaard Kristensen; Nam K Ku; Cecilia Arana Yi; Michael Boe Møller; Guido Marcucci; Linda Baughn; Ana-Iris Schiefer; J R Hilberink; Vinod Pullarkat; Ryan Shanley; Jessica Kohlschmidt; Janie Coulombe; Amandeep Salhotra; Lori Soma; Christina Cho; Michael A Linden; Cem Akin; Jason Gotlib; Gregor Hoermann; Jason Hornick; Ryo Nakamura; Joachim Deeg; Clara D Bloomfield; Daniel Weisdorf; Mark R Litzow; Peter Valent; Gerwin Huls; Miguel-Angel Perales; Gautam Borthakur
Journal:  Cancer Med       Date:  2018-08-16       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.